2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.

The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. While modern ART allows people living with HIV

While modern ART allows people living with HIV (PLWH) to lead near-normal lives, it cannot eliminate the "provirus"—the viral DNA that integrates into the host's own genome. If ART is stopped, this latent reservoir reactivates, leading to viral rebound. A permanent cure requires the physical removal or permanent silencing of this integrated DNA. this latent reservoir reactivates

Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free. While modern ART allows people living with HIV

Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub

In October 2022, PROVIREX announced a major expansion in Hamburg’s .

Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract